Test Catalog

Test ID: FIBNG    
Congenital Fibrinogen Disorders, FGA, FGB, and FGG Genes, Next-Generation Sequencing, Varies

Useful For Suggests clinical disorders or settings where the test may be helpful

Genetic confirmation of congenital disorders of fibrinogen with the identification of an alteration in FGA, FGB, or FGG that is known or suspected to cause disease


Testing for close family members of an individual with a diagnosis of afibrinogenemia/hypofibrinogenemia or dysfibrinogenemia/hypodysfibrinogenemia


This test is not intended for prenatal diagnosis

Genetics Test Information Provides information that may help with selection of the correct genetic test or proper submission of the test request

This test detects pathogenic alterations within the FGA, FGB, and FGG genes to delineate the underlying molecular defect in a patient with a laboratory diagnosis of congenital afibrinogenemia/hypofibrinogenemia or dysfibrinogenemia/hypodysfibrinogenemia.


The gene targets for this test are:

Gene name (transcript): FGA (GRCh37 [hg19] NM_021871)

Chromosomal location: 4q31.3


Gene name (transcript): FGB (GRCh37 [hg19] NM_005141)

Chromosomal location: 4q31.3


Gene name (transcript): FGG (GRCh37 [hg19] NM_000509)

Chromosomal location: 4q32.1

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

The laboratory workup for a congenital fibrinogen disorder begins with global coagulation screening assays.


In afibrinogenemia, prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin clotting time (TT) may be infinitely prolonged in afibrinogenemia.


In hypofibrinogenemia, TT is more sensitive than PT or aPTT for both quantitative and qualitative defects in fibrinogen.(1) Reptilase time (RT) maybe performed in addition to or instead of TT in samples known or suspected to contain heparin, which artificially prolongs TT.


PT, aPTT, and TT have poor sensitivity for mild fibrinogen deficiency or dysfunction. Further screening and identification of a mild fibrinogen deficiency or dysfibrinogenemia requires a clottable fibrinogen assay (typically Clauss-method based, eg, FIBTP / Fibrinogen, Plasma) to further test fibrinogen function as well as an immunologic (antigentic) assay (FIBAG / Fibrinogen Antigen, Plasma) to detect the quantity of fibrinogen present. Hypofibrinogenemia is indicated by a proportional decrease of functional and immunoreactive fibrinogen. Dysfibrinogenemia is indicated by a discrepancy between functional and immunoreactive fibrinogen.


Genetic testing for a congenital disorder of fibrinogen is indicated if:

-Coagulation tests indicate a quantitative or functional defect in fibrinogen

-Acquired causes of fibrinogen deficiency or dysfunction have been excluded (eg, thrombin clotting time [TT] may be prolonged by the presence of heparin, prior exposure to bovine thrombin, and high concentrations of serum proteins, as in multiple myeloma)

Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test

Fibrinogen forms the insoluble fibrin matrix that is a major component of the blood clots critical for stopping blood loss. Fibrinogen is made up of six polypeptide chains-one pair each of alpha, beta, and gamma chains (encoded by the FGA, FGB, and FGG genes respectively)-that are held together by 29 disulfide bonds.(2) The alpha, beta, and gamma fibrinogen subunits polymerize to form an insoluble fibrin matrix that is a major component of the blood clots critical for stopping blood loss. Fibrinogen also has a role in the early stages of wound repair.


Fibrinogen disorders are classified as either 1) afibrinogenemia or hypofibrinogenemia, a quantitative defect of low or absent fibrinogen plasma antigen levels, or 2) dysfibrinogenemia or hypodysfibrinogenemia, a qualitative defect in function and activity with normal or reduced antigen levels. Congenital afibrinogenemia and hypofibrinogenemia are inherited in an autosomal recessive manner. Congenital dysfibrinogenemia is, in most cases, inherited in an autosomal dominant manner but cases of recessive inheritance have also been reported.



Afibrinogenemia is characterized by the complete absence of fibrinogen in circulation. Although all individuals with afibrinogenemia have unmeasurable functional fibrinogen, the severity of bleeding is highly variable, even among those with the same genetic alteration(s).(3) Abnormal bleeding may occur in the neonatal period as umbilical cord bleeding. Bleeding may occur in skin, the oral cavity, gastrointestinal tract, genitourinary tract, or central nervous system. Intracranial hemorrhage is a major cause of death in affected individuals, who are also at risk for joint bleeds and spontaneous splenic rupture. Venous and arterial thromboembolic complications and poor wound healing may also occur. Affected women have increased risk for menometrorrhagia and recurrent pregnancy loss. The prevalence of afibrinogenemia is estimated to be 1 in 1 million.



Most individuals with hypofibrinogenemia (characterized by fibrinogen levels less than 1.5 g/L) are asymptomatic.(3) Thromboembolism may occur spontaneously or with fibrinogen substitution therapy. Affected individuals may experience abnormal bleeding after trauma or if they have a second hemostatic abnormality. Recurrent pregnancy loss and postpartum hemorrhage are reported in affected women. There is typically good correlation between fibrinogen levels and clinical severity, with levels less than 0.5 g/L associated with major bleeding.(4) Specific alterations associated with hypofibrinogenemia are strongly correlated with hepatic storage disease.(3) Acquired hypofibrinogenemia has been reported in individuals with hepatic failure or decompensation cirrhosis. Hypofibrinogenemia is also commonly associated with acute disseminated intravascular coagulation (DIC). Less common acquired causes include administration of L-asparaginase and valproic acid or other drugs that impair hepatic synthesis. These causes of acquired hypofibrinogenemia should be excluded prior to genetic testing for a fibrinogen disorder.


Dysfibrinogenemia and Hypodysfibrinogenemia:

About half of individuals with dysfibrinogenemia and hypodysfibrinogenemia are asymptomatic. However, alteration carriers carry a high risk of major bleeding and/or thromboembolic complications.(5) Patients bleed most after trauma, surgery, or postpartum. Some women have spontaneous abortions. Specific alterations associated with dysfibrinogenemia are strongly associated with thromboembolic pulmonary hypertension and amyloidosis. Causes of acquired (non-genetic) dysfibrinogenemia or defects in fibrinogen that should be excluded prior to genetic testing include cirrhosis, acute or chronic hepatitis, metastatic hepatoma, renal carcinoma, and biliary obstruction. Individuals treated with isotretinoin therapy have also been reported to develop acquired dysfibrinogenemia. Fibrinogen antibodies and inhibitors have been reported in systemic lupus erythematosus, ulcerative colitis, and multiple myeloma. These causes of acquired dysfibrinogenemia and hypodysfibrinogenemia should be considered and excluded prior to genetic testing for a fibrinogen disorder.

Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.

An interpretive report will be provided

Interpretation Provides information to assist in interpretation of the test results

An interpretive report will be provided.


Evaluation and categorization of variants is performed using the most recent published American College of Medical Genetics and Genomics (ACMG) recommendations as a guideline. Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.


Consultations with the Mayo Clinic Special Coagulation Clinic, Molecular Hematopathology Laboratory, or Thrombophilia Center are available for DNA diagnosis cases. This may be especially helpful in complex cases or in situations where the diagnosis is atypical or uncertain.

Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances


Some individuals may have a mutation that is not identified by the methods performed. The absence of a mutation, therefore, does not eliminate the possibility of afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, thrombophilia, bleeding tendency, familial visceral amyloidosis, or fibrinogen storage disease. This assay does not distinguish between germline and somatic alterations, particularly with variant allele frequencies (VAF) significantly lower than 50%. Test results should be interpreted in context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.


Technical Limitations:

Next-generation sequencing (NGS) may not detect all types of genetic variants. Additionally, rare polymorphisms may be present that could lead to false negative or positive results. Therefore test results should be interpreted in the context of activity and antigen measurements, clinical findings, family history, and other laboratory data. If results do not match clinical findings, consider alternative methods for analyzing these genes, such as Sanger sequencing or large deletion/duplication analysis. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.


If multiple alterations are identified, NGS is not able to distinguish between alterations that are found in the same allele ("in cis") and alterations found on different alleles ("in trans"). This limitation may complicate diagnosis or classification and has implications for inheritance and genetic counseling. To resolve these cases, molecular results must be correlated with clinical history, activity and antigen measurements, and family studies.


Unless reported or predicted to cause disease, alterations found deep in the intron or alterations that do not result in an amino acid substitution are not reported. These and common polymorphisms identified for this patient are available upon request.


Reclassification of Variants Policy: At this time, it is not standard practice for the laboratory to systematically review likely pathogenic variants or variants of uncertain significance that are detected and reported. The laboratory encourages health care providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time.

Clinical Reference Recommendations for in-depth reading of a clinical nature

1. Verhovsek M, Moffat KA, Hayward CP: Laboratory testing for fibrinogen abnormalities. Am J Hematol. 2008;83(12):928-931

2. Weisel J and Litvinov R: Mechanisms of fibrin polymerization and clinical implications. Blood. 2013;121:1712-1719

3. De Moerloose P, Casini A, Neerman-Arbez M: Congenital fibrinogen disorders: an update. Semin Thromb Hemost. 2013;39:585-595

4. De Moerloose P, Schved JF, Nugent D: Rare coagulation disorders: fibrinogen, factor VII and factor XIII. Haemophilia. 2016;22(Suppl 5):61-65

5. Casini, A, Blondon M, Lebreton A, et al: Natural history of patients with congenital dysfibrinogenemia. Blood. 2015;125:553-561

6.Casini A, Neerman-Arbez M, Ariens RA: Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost. 2015;13(6):909-919

7. Peyvandi F: Epidemiology and treatment of congenital fibrinogen deficiency. Thromb Res. 2012;130(Suppl 2):S7-11

Special Instructions Library of PDFs including pertinent information and forms related to the test